← Leaderboards
Matthew D Volm
New York University School Of Medicine
$0
Attributed
$0
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 3
By mechanism
M01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Jay Cooper$168,048
- Franco M Muggia$5,360,861
- Matthew Volm$84,024
- William N Rom$26,662,104
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchNeoplasm /Cancer ChemotherapyHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer SurgeryBreast NeoplasmsDoxorubicinHodgkin'S DiseaseLiposomesMonoclonal AntibodyNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Relapse /RecurrenceOncoproteinsPaclitaxelProdrugsSarcomaTemozolomideAntineoplasticsTumor AntigensAntitumor AntibodyCombination Cancer TherapyCombination ChemotherapyCyclophosphamide
Grant awards (6)
SERUM HER 2 ECDO ANTIGEN IN BREAST CANCER$0
M01 · FY2000 · RR
SERUM HER 2 ECDO ANTIGEN IN BREAST CANCER$0
M01 · FY2000 · RR
TEMODAL IN PATIENTS WITH ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
TEMODAL IN PATIENTS WITH ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
HERCEPTIN, PACLITAXEL IN BREAST CANCER W/ HER2 EXPRESSIO$0
M01 · FY2000 · RR
HERCEPTIN, PACLITAXEL IN BREAST CANCER W/ HER2 EXPRESSIO$0
M01 · FY2000 · RR